Gilead Sciences (NASDAQ:GILD) Given New $95.00 Price Target at Barclays

Gilead Sciences (NASDAQ:GILD) had its price objective boosted by Barclays from $84.00 to $95.00 in a research note released on Thursday morning,Benzinga reports. Barclays currently has an equal weight rating on the biopharmaceutical company’s stock.

A number of other research firms have also recently commented on GILD. Leerink Partnrs upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 21st. Wells Fargo & Company lifted their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday. JPMorgan Chase & Co. increased their price target on Gilead Sciences from $95.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 9th. Truist Financial upped their price objective on Gilead Sciences from $82.00 to $83.00 and gave the stock a “hold” rating in a research note on Thursday, August 15th. Finally, Piper Sandler lifted their target price on Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday. Eleven analysts have rated the stock with a hold rating, ten have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $91.50.

Gilead Sciences Trading Down 1.4 %

NASDAQ:GILD opened at $96.57 on Thursday. Gilead Sciences has a one year low of $62.07 and a one year high of $98.32. The business has a fifty day moving average price of $85.30 and a 200-day moving average price of $75.09. The firm has a market capitalization of $120.23 billion, a price-to-earnings ratio of 1,073.00, a price-to-earnings-growth ratio of 3.36 and a beta of 0.17. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.11 and a quick ratio of 0.95.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same quarter in the prior year, the business posted $2.29 earnings per share. The business’s quarterly revenue was up 7.0% on a year-over-year basis. Sell-side analysts forecast that Gilead Sciences will post 4.34 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 3.19%. The ex-dividend date of this dividend is Friday, December 13th. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Insider Buying and Selling

In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now owns 78,127 shares in the company, valued at $6,545,480.06. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, insider Merdad Parsey sold 25,590 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the transaction, the insider now owns 99,599 shares of the company’s stock, valued at approximately $9,113,308.50. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 62,437 shares of company stock worth $5,374,825 over the last three months. 0.16% of the stock is owned by insiders.

Institutional Trading of Gilead Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. CarsonAllaria Wealth Management Ltd. grew its holdings in shares of Gilead Sciences by 198.3% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 238 shares during the last quarter. nVerses Capital LLC purchased a new stake in Gilead Sciences in the 3rd quarter valued at about $25,000. Valued Wealth Advisors LLC grew its stake in Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 161 shares in the last quarter. Cedar Wealth Management LLC increased its position in shares of Gilead Sciences by 51.6% during the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 160 shares during the period. Finally, Strategic Investment Solutions Inc. IL purchased a new stake in shares of Gilead Sciences in the second quarter valued at approximately $33,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.